As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Barinthus Biotherapeutics plc. The largest reported stake is International Generosity Foundation Trust's, at 6.7%. 2 filings are on record since April 13, 2026 (Schedule 13D, April 13, 2026).
Sell to companies like Barinthus Biotherapeutics plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Barinthus Biotherapeutics plc. has 2 Schedule 13D or 13G filings on record since 2026-04-13. 1 holder's latest filing reports 5% or more of american depositary shares, each representing one ordinary share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| International Generosity Foundation Trust | 6.7% | 2,734,189 | SCHEDULE 13D, 2026-04-13 | 2026-02-03 |
| Oxford Science Enterprises plc | 0% | 0 | SCHEDULE 13G/A, 2026-09-11 | 2026-09-09 |
Holding shares or following this stake? See who's behind Barinthus Biotherapeutics plc. and the warning signs.
Free to see. No signup.
Keep reading
More on Barinthus Biotherapeutics plc. and the records around it.
Barinthus Biotherapeutics plc. elsewhere on the record
- Acquisition Sep 2026
- Leadership changes Apr 2026
Companies that share a holder
- Oxford Science Enterprises plc also filed stake reports on 1 other company: PepGen Inc. (Oct 2025)
Watch Barinthus Biotherapeutics plc.
Get an email when Barinthus Biotherapeutics plc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Barinthus Biotherapeutics plc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Barinthus Biotherapeutics plc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Barinthus Biotherapeutics plc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| International Generosity Foundation Trust | 2,734,189 | 0 | 2,734,189 | 0 | SCHEDULE 13D, 2026-04-13 |
| Oxford Science Enterprises plc | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-09-11 |
The latest filing identifies Barinthus Biotherapeutics plc. by CUSIP 91864C107 and gives its principal executive office as 20400 CENTURY BLVD, SUITE 210, GERMANTOWN, MD 20874 (SCHEDULE 13G/A, 2026-09-11).
Source of funds (Item 3)
The securities reported herein were acquired by the Reporting Person through a combination of purchases and transfers. A portion of the securities was acquired using the working capital of the Reporting Person. The Reporting Person is a non-profit trust generally funded through donations, including donor-advised funds. The remaining securities were acquired through transfers or contributions to the Reporting Person and were not acquired through the use of funds.International Generosity Foundation Trust, SCHEDULE 13D, 2026-04-13
Purpose of Transaction (Item 4)
International Generosity Foundation Trust
The Reporting Person acquired the securities for investment purposes and in connection with its charitable activities. The Reporting Person may, from time to time, sell or otherwise dispose of some or all of the securities, including to support its charitable purposes, or acquire additional securities, depending on market conditions and other factors. Except as set forth above, the Reporting Person has no present plans or proposals that relate to or would result in any of the actions described in Items 4(a) through (j) of Schedule 13D.Item 4 of the SCHEDULE 13D filed 2026-04-13
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-04-13 | International Generosity Foundation Trust | 6.7% | SCHEDULE 13D |
| 2026-09-11 | Oxford Science Enterprises plc | 0% | SCHEDULE 13G/A |
Questions about who owns Barinthus Biotherapeutics plc.
Who owns Barinthus Biotherapeutics plc.?
On this page, one holder's latest ownership filing reports 5% or more of Barinthus Biotherapeutics plc.: International Generosity Foundation Trust (6.7%, Schedule 13D, filed 2026-04-13).
When did International Generosity Foundation Trust buy into Barinthus Biotherapeutics plc.?
The filings give report dates, not purchase dates. The earliest filing from International Generosity Foundation Trust on this page is the Schedule 13D, filed 2026-04-13, reporting 6.7%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Barinthus Biotherapeutics plc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 9, 2026 | Acquired by Beacon Topco, Inc. | — | Acquisition | Source |
| April 22, 2026 | Leadership change: Douglas Swirsky appointed, Chief Financial Officer | — | Leadership changes | Source |
| March 31, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Barinthus Biotherapeutics plc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.